World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
26024
World Ranking
13250
National Ranking
6749

Overview

Xuemei Wang is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical and oncological fields, contributing extensively to several subfields such as pulmonary and respiratory medicine, hematology, oncology, surgery, and genetics.

The main topics of Wang's work include acute myeloid leukemia research, gastric cancer management and outcomes, chronic lymphocytic leukemia research, prostate cancer treatment and research, chronic myeloid leukemia treatments, prostate cancer diagnosis and treatment, and colorectal cancer treatments and studies.

Wang has published numerous papers in high-profile journals. Some selected recent publications are:

  • Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study, 2021, Journal for ImmunoTherapy of Cancer
  • Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia, 2022, Journal of Clinical Oncology
  • Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia, 2021, JAMA Oncology
  • Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy, 2022, Blood Cancer Journal
  • The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development, 2020, Clinical Cancer Research

Wang collaborates frequently with several other researchers, including:

  • Hagop M. Kantarjian
  • Tapan M. Kadia
  • Naveen Pemmaraju
  • Nitin Jain
  • Courtney D. DiNardo

Their work is often published in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, The Journal of Urology, and Oncology.

Wang has contributed significantly to the field of medicine, with 247 publications primarily related to their main area of expertise. The subfields reflect focused investigations into respiratory and hematologic conditions, surgical interventions, and genetic factors influencing disease.

Best Publications

  • Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

    Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  • Body surface area and body weight predict total liver volume in Western adults

    Jean Nicolas Vauthey;Eddie K. Abdalla;Dorota A. Doherty;Philippe Gertsch

  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

    Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang

  • Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

    Christos N. Papandreou;Danai D. Daliani;Darrell Nix;Hong Yang

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Fingerprinting the circulating repertoire of antibodies from cancer patients

    Paul J. Mintz;Jeri Kim;Kim Anh Do;Xuemei Wang

  • Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.

    Milena S. Nicoloso;Hao Sun;Hao Sun;Riccardo Spizzo;Hyunsoo Kim

  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

    Melanie B. Thomas;Romil Chadha;Katrina Glover;Xuemei Wang

  • PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang

  • Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy.

    Philippe E. Spiess;Andrew K. Lee;Dan Leibovici;Xuemei Wang

  • The Crosstalk of mTOR/S6K1 and Hedgehog Pathways

    Yan Wang;Qingqing Ding;Chia Jui Yen;Weiya Xia

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • Guidelines for Reporting of Statistics for Clinical Research in Urology.

    Melissa Assel;Daniel Sjoberg;Andrew Elders;Xuemei Wang

  • High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

    Stefan O. Ciurea;Marcos J.G. de Lima;Pedro Cano;Martin Korbling

  • Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate

    Christos N. Papandreou;Danai D. Daliani;Peter F. Thall;Shi Ming Tu

  • Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

    Min S. Park;Shreyaskumar R. Patel;Joseph A. Ludwig;Jonathan C. Trent

  • Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

    Borje S. Andersson;Peter F. Thall;Timothy Madden;Daniel Couriel

  • Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

    Ana M. Aparicio;Li Shen;Elsa M Li Ning Tapia;Jing-Fang Lu

  • Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

    Taghi Manshouri;Kim Anh Do;Xuemei Wang;Francis J. Giles

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Jaffer A. Ajani
Jaffer A. Ajani The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine often means exploring versatile pathways and continued education options. Many students are now turning to online programs for added flexibility and diverse opportunities within the healthcare field.

For those interested in healthcare administration, top cahme-accredited mha programs offer rigorous online curricula and accreditation, essential for leadership roles in hospitals and clinics.

Nurses seeking to advance their credentials can look into online rn to bsn programs without clinicals. These options are ideal for working professionals who want to deepen their knowledge without the additional scheduling challenges of in-person clinical rotations.

Aspiring nurse practitioners and leaders might consider the fastest online dnp programs, enabling them to reach the highest level of nursing practice in less time.

For those who prefer a more streamlined doctoral experience, some dnp programs without dissertation offer an accelerated path, focusing on practical leadership rather than traditional research.

Best Scientists Citing Xuemei Wang

Trending Scientists

Recently Published Articles